Expression of lysophosphatidic acid acyltransferase beta (LPAAT-β) in ovarian carcinoma: Correlation with tumour grading and prognosis

S. Niesporek, C. Denkert, W. Weichert, M. Köbel, A. Noske, J. Sehouli, J. W. Singer, M. Dietel, S. Hauptmann

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Lysophosphatidic acid acyltransferase beta (LPAAT-β) is an enzyme involved in lipid biosynthesis whose role in tumour progression has been of emerging interest in the last few years. We investigated the expression of LPAAT-β by reverse transcriptase-polymerase chain reaction and immunohistochemistry in 10 ovarian cell lines as well as in a cohort of 106 ovarian tumours and normal ovaries. Lysophosphatidic acid acyltransferase beta mRNA was found in all cell lines and ovarian tumours examined. Expression of LPAAT-β protein was significantly increased in ovarian carcinomas compared to benign ovarian tissue (χ2 test P-value = 0.001, Kruskal-Wallis test P-value < 0.0001). Furthermore, LPAAT-β expression was positively associated with higher tumour grade (P = 0.044), higher mitotic index (P < 0.0001) and tumour stage (P = 0.032). Expression of LPAAT-β was significantly linked to reduced overall survival time (P = 0.024) as well as to shorter progression-free survival time (P = 0.012) in patients younger than 60 years. Our study shows that LPAAT-β is upregulated in ovarian cancer and is more prevalent in poorly differentiated tumours. In addition, LPAAT-β expression is a predictor of a worse prognosis in patients younger than 60 years. Further studies are needed to investigate if LPAAT-β may serve as a therapeutic target for certain subgroups of patients.

Original languageEnglish
Pages (from-to)1729-1736
Number of pages8
JournalBritish Journal of Cancer
Volume92
Issue number9
DOIs
StatePublished - 9 May 2005
Externally publishedYes

Keywords

  • LPAAT-β
  • Ovarian cancer
  • Phosphatidic acid

Fingerprint

Dive into the research topics of 'Expression of lysophosphatidic acid acyltransferase beta (LPAAT-β) in ovarian carcinoma: Correlation with tumour grading and prognosis'. Together they form a unique fingerprint.

Cite this